Prosper AI vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC S23 healthcare AI phone agents automating 50-70% of inbound calls for scheduling, prior auth, and claims; $5M Emergence Capital seed Sep 2025 with 4x revenue growth competing with Nuance and Luma Health for the $200B healthcare admin voice automation market.
About
Prosper AI is a San Francisco-based healthcare AI voice automation company — backed by Y Combinator (S23) with $5 million in seed funding in September 2025 led by Emergence Capital — providing healthcare providers with AI phone agents that automate inbound patient call workflows including patient scheduling, balance reminders, claims status checks, benefits verification, and prior authorization status inquiries — achieving 50-70% inbound call automation rates with 99% IVR navigation accuracy. Founded in 2023 by Josep Mingot and Xavier de Gracia (MIT and Harvard alumni), Prosper AI achieved 4x revenue growth since Q2 2025, addressing the $450 billion US healthcare administrative overhead crisis where an estimated $200 billion in administrative costs come from phone-based patient-provider communication inefficiencies.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.